A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

Inclusion Criteria: * Aged between 18 and 75 years (inclusive), regardless of gender. * Body weight ≥50.0 kg for males and ≥45.0 kg for females; body mass index (BMI) between 19.0 and 35.0 kg/m² (inclusive). * For participants with renal impairment: prior diagnosis of chronic kidney disease (CKD). Absolute GFR calculated by CKD-EPI and BSA formula: ≥30 and \<60 mL/min for moderate impairment; ≥15 and \<30 mL/min for severe impairment. * For participants with normal renal function: aged 18 to 75 years (inclusive); body weight ≥50.0 kg (male) or ≥45.0 kg (female); BMI 19.0-35.0 kg/m². * In the investigator's opinion, suitable for the study based on medical history, clinical laboratory tests, vital signs, 12-lead ECG, and physical examination at screening. * Provide signed informed consent before any trial procedures; fully understand the trial content, procedures, and possible adverse reactions. * Able to communicate well with the investigator and understand and comply with all study requirements. Exclusion Criteria: * Personal or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2). * History of chronic pancreatitis, or an episode of acute pancreatitis or acute cholecystitis within 3 months prior to screening. * Severe hypoglycemic events or recurrent hypoglycemic events (≥3 episodes per week) within 3 months prior to screening. * For the renal impairment group: presence of obstructive urinary tract d…